|
|
 |
|
Viewing report
|
|
|
|
Lessons Learned from the Current Crop of Biotech Startups
Decision Resources, Inc., Aug 2008, Pages: 40
This report features three Spectrum Expert Commentaries—one offers insight from the perspective of a biotech startup, another offers advice from a renowned cancer biologist to young companies that want to go public or have been public and are struggling, and the other highlights an emerging area of biotech startups. Analysis from six in-depth interviews of diverse biotech startups is also included in the report.
The initial public offering (IPO) market for biotech and specialty pharma companies has been nearly lifeless in 2008. Investment bankers are unimpressed by the performance of these companies, and money managers are reluctant to support a negative trend. The other side of intense pessimism, however, is that money accumulates on the sidelines where life science investors ultimately become impatient with money market returns and look for places to put risk capital to work. We demystify the best way to navigate the startup route through three in-depth Spectrum Expert Commentaries. A fresh and comprehensive look at IPOs and industry trends demonstrates that the future is not all bleak.
Get the Answers You Need to Shape Your Strategy
- Having raised enough money, filed the sufficient forms, and ensured your leading compound is in the intended phase of development are all important factors in the decisions companies make before going public. What steps, when implemented, will further the likelihood of a successful IPO filing? How can competitors’ strategies be interpreted based on their decisions?
- Despite the unstable state of today’s economy, not every startup is aiming to be acquired by a larger firm. What exit strategies are particularly common among those biotech startups that are performing well? What motivates the investors that are observing from the sidelines?
- Expert opinion is unanimous: establishing a strong game plan early in the process of the pathway to going public—and sticking to it—is essential. How can a biopharma or diagnostics company looking to invest in a startup influence that process to create a win-win for all parties involved?
Scope
- Overview of the biotechnology startup landscape: market overview, market performance, 2007- 2008 IPOs, status of startups’ lead compounds in development.
- Company profiles: detailed company profiles of six startups that are making strides in today’s tough economy—Molecular Insight Pharmaceuticals, NeurogesX, NovaBay Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, and Rosetta Genomics.
- Spectrum Expert Commentaries: in-depth analysis from innovative, accomplished, and renowned scientist entrepreneurs who provide valuable strategic insight and advice to early-stage companies.
- Specific insight for young companies: advice on how to plan for the IPO road show; issues to consider regarding investor relations; and the advantages of a strong management team.
Customers who bought this item also bought
Optimer Pharmaceuticals Inc: Premium Company Profile
Novabay Pharmaceuticals, Inc.
Optimer Pharmaceuticals Inc
InsideChips - Focused on Semiconductor Innovation and Startups
China Biotech 2008
Biotech 2009-Life Sciences: Navigating the Sea Change
Small Business Finance in the United States Volume 1: Startups
Lifecycle of a Technology Company : Step-by-Step Legal Background and Practical Guide from Startup to Sale
Biotech Life Sciences: A 20/20 Vision to 2020
2006 Financings: IPOs and Pharmas Acquisitions of Private (IPO-less) Companies
Molecular Insight Pharmaceuticals Inc
Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape
|
|
|
|
